Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Venus Remedies Enoxaparin vs Clexane in Healthy Adults
NCT05265676Phase 1Completed
- Sponsor
- Venus Remedies
- Start
- Feb 2021
- Primary completion
- Mar 2021
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Cloti-Xa in venous thromboembolism (VTE) (2 arms), sponsored by Venus Remedies. Primary endpoints: Maximum Activity (Amax) for Anti-Xa, Maximum Activity (Amax) for Anti-IIa and 2 more. Started Feb 2021; status: completed.
02
Drugs
Cloti-Xa
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05265676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265676.